BridgeBio Pharma(NASDAQ) BBIO

BridgeBio Pharma, Inc. makes medicines for people with rare genetic diseases. These treatments help patients by targeting specific genetic causes of their conditions. The company identifies and develops therapies for groups with few medical options.

Treating Rare Genetic Conditions

• ATTR Therapies: Medical solutions for transthyretin amyloidosis-cardiomyopathy, a condition involving protein buildup that damages the heart.
• Skeletal Dysplasia Treatments: Pipeline candidates like infigratinib for children with achondroplasia, which is the most common form of short-limbed dwarfism.
• Muscular Dystrophy Candidates: Developmental therapies such as BBP-418 for limb-girdle muscular dystrophy, a disease causing progressive muscle weakness.
• Endocrine Disorder Solutions: Small molecule treatments like encaleret for Autosomal Dominant Hypocalcemia Type 1, which causes abnormally low blood calcium levels.

Expanding Through Global Partnerships

• Partnered with Bayer in March 2024 to develop and commercialize acoramidis for heart patients in Europe.
• Licensed infigratinib to Kyowa Kirin in February 2024 for development and sales in Japan.
• Secured $933.9 million in July 2026 through the sale of preferred stock to Sixth Street and HCRx.
• Submitted a New Drug Application to the FDA for BBP-418 in March 2026 for treating muscle disease.
• Repaid a $450 million term loan in February 2025 using proceeds from a senior notes offering.

A Distributed Research Model

BridgeBio uses a portfolio-based model to manage dozens of drug development programs simultaneously. This approach allows the firm to share resources like accounting and legal services across many different research projects.

Revenue Growth and Capital Management

• Total revenues were $438.2 million for the six months ended June 30, 2026, up from $227.2 million in the same period in 2025.
• Net product revenue reached $403.0 million for the six months ended June 30, 2026, up from $108.2 million year over year.
• Net loss was $322.4 million for the six-month period ended June 30, 2026.
• Market cap reached $14.5 billion in Q2 2026, up 76.8% year over year.
• Total cash, cash equivalents, and marketable securities were $720.2 million as of June 30, 2026.

The Path Forward

BridgeBio has transitioned from a research-focused firm to a commercial-stage company with a growing revenue base from its approved heart medication. Its strategy relies on advancing a broad pipeline of genetic therapies while securing diverse funding sources to support long-term development.